The Corpus Content Team

MS Awareness Month

Submitted by krupa.mistry on Thu, 24/03/2022 - 11:01

March is MS awareness month and is a great opportunity to give people confidence to speak up and share stories. The goal of this month for the National MS Society is to “help people better understand life with MS and become inspired to do whatever it takes to change the world for people living with [the condition]”.1 

Medical Affairs Professionals Society conference 2022

Submitted by krupa.mistry on Tue, 15/03/2022 - 16:58

The Corpus is excited to be attending the Medical Affairs Professionals Society conference in New Orleans, Louisiana next week. Over 700 Medical Affairs professionals from around the world will gather at the conference which will feature industry-leading programming, best practice sharing, and plenty of opportunities for networking. This will be our first live event since 2020 and we are looking forward to seeing everyone in person again! 

The changing landscape of epilepsy treatments: what does the future hold?

Submitted by krupa.mistry on Mon, 21/02/2022 - 11:29

Epilepsy affects approximately 50 million people worldwide and The WHO estimates that up to 70% (1) of them could live seizure-free if properly diagnosed and treated. Epilepsy is a chronic disease of the central nervous system which affects people of all ages, ethnicities, locations and socio-economic backgrounds.

The increasing adoption of augmented reality tech in medicine and healthcare

Submitted by krupa.mistry on Tue, 18/01/2022 - 14:29

Augmented reality (AR) is a technology that integrates interactive virtual content with the physical real world, such as in the form of a digital three-dimensional visual (3D) representation, thereby augmenting the perception of reality. Typically, virtual content is projected into the physical environment through the use of smart glasses, a headset or mobile/tablet device (1, 2, 3). AR is one of the most exciting technological advances in medicine and healthcare in recent times, with many novel applications being developed for use in improving patient outcomes.

Expansion, carbon-neutrality and augmented reality: just a few things we’ve addressed in 2021

Submitted by Jan Ash on Wed, 22/12/2021 - 09:06

This time last year we were reflecting on the light at the end of the tunnel, with a vaccine being rolled out that would help fight COVID-19. The global situation has certainly improved since then but, unfortunately, we aren’t quite out the other side just yet. 2021 repeatedly threw challenges our way and businesses were forced to continue to adapt and evolve in order to survive. As an online education provider we were in a very fortunate position, and we’ve successfully run hundreds of online meetings over the past 12 months.

The future of non-small-cell lung cancer diagnosis and treatment

Submitted by krupa.mistry on Tue, 16/11/2021 - 08:51

Lung cancer is the most common cause of cancer-related death worldwide, of which the vast majority is non-small-cell lung cancer (NSCLC)(1). Early-stage NSCLC can be treated with surgery alone, while later stages are likely to also require adjuvant or combination therapies such as radiotherapy, chemotherapy and immunotherapy. If gene mutations are detected among cancer cells, then targeted therapy could also be administered.

AI-assisted endoscopy: A genial tool against colorectal cancer

Submitted by Jan Ash on Thu, 24/06/2021 - 10:24

The use of AI to aid diagnosis has been heralded increasingly often as an imminent evolution in the world of gastroenterology (1, 2). Thanks to an Italian study, in April the FDA has approved for the first time a tool for colonoscopy that helps doctors detect suspicious lesions in real time whilst performing the examination (3, 4).

Multimarker approaches to Heart Failure therapy and beyond

Submitted by Jan Ash on Tue, 13/04/2021 - 07:44

Heart failure (HF) is a pressing and illusive public health epidemic. Nearly 50% of all HF cases involve HFpEF — to which there is no defined therapy (1). As such, refining prediction and treatment of HF is a crucial step in alleviating high morbidity and mortality (2). The development of novel clinical tools and therapies that assist in the diagnosis and management of HF, such as the use of biomarkers, are essential to improving patient outcomes.